Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

被引：12
|
作者：
Grossmann, Kenneth F.
Othus, Megan
Patel, Sapna Pradyuman
Tarhini, Ahmad A.
Sondak, Vernon K.
Petrella, Teresa M.
Truong, Thach-Giao
Khushalani, Nikhil I.
Cohen, Justine Vanessa
Buchbinder, Elizabeth Iannotti
Kendra, Kari Lynn
Funchain, Pauline
Lewis, Karl D.
Chmielowski, Bartosz
Li, Hongli
Moon, James
Gunturu, Krishna Soujanya
Eroglu, Zeynep
Kirkwood, John M.
Ribas, Antoni
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[7] Kaiser Permanente, Dept Med Oncol, Vallejo, CA USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[11] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH USA
[12] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA
[13] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA
[14] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA USA
[15] SWOG, Seattle, WA USA
[16] Southwest Oncol Grp Stat Ctr, Seattle, WA USA
[17] Lahey Hosp & Med Ctr, Burlington, MA USA
[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[19] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[20] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9501
引用
收藏
页数：3
相关论文
共 26 条
  • [1] SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Kirkwood, John M.
    Moon, James
    Sondak, Vernon K.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Moon, James
    Sondak, Vernon K.
    Kirkwood, John M.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial
    Unger, Joseph M.
    Darke, Amy
    Othus, Megan
    Truong, Thach-Giao
    Khushalani, Nikhil
    Kendra, Kari
    Lewis, Karl D.
    Faller, Bryan
    Funchain, Pauline
    Buchbinder, Elizabeth I.
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Sharon, Elad
    Sondak, Vernon
    Guild, Samantha R.
    Grossmann, Kenneth
    Ribas, Antoni
    Patel, Sapna P.
    [J]. JAMA ONCOLOGY, 2023, 9 (02) : 251 - 260
  • [4] Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)
    Agarwala, S. S.
    Lee, S. J.
    Flaherty, L. E.
    Smylie, M.
    Kefford, R. F.
    Carson, W. E.
    Cohen, G.
    Kirkwood, J. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary Irvin
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A phase Ill randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404
    Grossmann, Kenneth F.
    Sondak, Vernon K.
    Othus, Megan
    Tarhini, Ahmad
    Patel, Sapna
    Kirkwood, John M.
    Ribas, Antoni
    Moon, James
    [J]. CANCER RESEARCH, 2016, 76
  • [7] Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
    Kilbridge, KL
    Cole, BF
    Kirkwood, JM
    Haluska, FG
    Atkins, MA
    Ruckdeschel, JC
    Sock, DE
    Nease, RF
    Weeks, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1311 - 1318
  • [8] CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma
    Samlowski, Wolfram E.
    Moon, James
    Witter, Merle
    Atkins, Michael B.
    Kirkwood, John M.
    Othus, Megan
    Ribas, Antoni
    Sondak, Vernon K.
    Flaherty, Lawrence E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [10] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
123